Evidence map›Paper›PMID 34389043›Full record

ArticleClinical epigenetics2021

A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease.

Sara Diels, Bart Cuypers, Asta Tvarijonaviciute, Bruno Derudas, Evelien Van Dijck, An Verrijken, Luc F Van Gaal, Kris Laukens, Philippe Lefebvre, Jose J Ceron and 3 more

Open access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Multi-omics dissection of RAD21-PON1 axis reveals metabolic-immune crosstalk and prognostic significance in hepatocellular carcinoma.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. A Case-Control Study Supports Genetic Contribution of theAntioxidants (Basel, Switzerland) · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. The Relationship between Cancer and Paraoxonase 1.Antioxidants (Basel, Switzerland) · 2022
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Sara DielsDepartment of Medical Genetics, University of Antwerp, Prins Boudewijnlaan 43, 2650, Edegem, Antwerp, Belgium.
Bart CuypersMolecular Parasitology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Asta TvarijonaviciuteInterdisciplinary Laboratory of Clinical Analysis INTERLAB-UMU, University of Murcia, Murcia, Spain.
Bruno DerudasInserm, CHU Lille, Pasteur Institute of Lille, University of Lille, Lille, France.
Evelien Van DijckDepartment of Medical Genetics, University of Antwerp, Prins Boudewijnlaan 43, 2650, Edegem, Antwerp, Belgium.
An VerrijkenDepartment of Endocrinology, Diabetology and Metabolic Disease, Antwerp University Hospital, Antwerp, Belgium.
Luc F Van GaalDepartment of Endocrinology, Diabetology and Metabolic Disease, Antwerp University Hospital, Antwerp, Belgium.
Kris LaukensMolecular Parasitology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Philippe LefebvreInserm, CHU Lille, Pasteur Institute of Lille, University of Lille, Lille, France.
Jose J CeronInterdisciplinary Laboratory of Clinical Analysis INTERLAB-UMU, University of Murcia, Murcia, Spain.
Sven FrancqueLaboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
Wim Vanden BergheDepartment of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Wim Van HulDepartment of Medical Genetics, University of Antwerp, Prins Boudewijnlaan 43, 2650, Edegem, Antwerp, Belgium. wim.vanhul@uantwerpen.be.ORCID 0000-0002-5065-7858
University of Antwerp · BEInserm · FRUniversidad de Murcia · ES

Funding

European Commission LSHM-CT-2005-018734Fonds De La Recherche Scientifique - FNRS 11E6921NFonds De La Recherche Scientifique - FNRS 12V5319NFonds De La Recherche Scientifique - FNRS 1802154NGOA FFB180348/36572Methusalem-OEC FFB190208RESOLVE FP7-305707
6 · The paper itself

Abstract

backgroundThe multifactorial nature of non-alcoholic fatty liver disease cannot be explained solely by genetic factors. Recent evidence revealed that DNA methylation changes take place at proximal promoters within susceptibility genes. This emphasizes the need for integrating multiple data types to provide a better understanding of the disease's pathogenesis. One such candidate gene is paraoxonase-1 (PON1). Substantial interindividual differences in PON1 are apparent and could influence disease risk later in life. The aim of this study was therefore to determine the different regulatory aspects of PON1 variability and to examine them in relation to the predisposition to obesity-associated fatty liver disease.

resultsA targeted multi-omics approach was applied to investigate the interplay between PON1 genetic variants, promoter methylation, expression profile and enzymatic activity in an adult patient cohort with extensive metabolic and hepatic characterisation including liver biopsy. Alterations in PON1 status were shown to correlate with waist-to-hip ratio and relevant features of liver pathology. Particularly, the regulatory polymorphism rs705379:C > T was strongly associated with more severe liver disease. Multivariable data analysis furthermore indicated a significant association of combined genetic and epigenetic PON1 regulation. This identified relationship postulates a role for DNA methylation as a mediator between PON1 genetics and expression, which is believed to further influence liver disease progression via modifications in PON1 catalytic efficiency.

conclusionsOur findings demonstrate that vertical data-integration of genetic and epigenetic regulatory mechanisms generated a more in-depth understanding of the molecular basis underlying the development of obesity-associated fatty liver disease. We gained novel insights into how NAFLD classification and outcome are orchestrated, which could not have been obtained by exclusively considering genetic variation.

Indexed as

Genetic Predisposition to DiseaseAdolescentAdultAgedAryldialkylphosphataseDNA MethylationEpigenesis, GeneticFemaleHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseObesityYoung AdultAryldialkylphosphataseGeneticsIntegrative analysisMethylationNAFLDObesity-OmicsPON1

Identifiers

PMID34389043
PMCPMC8360816
OpenAlexW3192959321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.